of Esophageal Adenocarcinoma patients never knew they had treatable Barrett's Esophagus
Find Barrett's before it progresses
#1 rate of increase of any cancer
in the past 4 decades
Less than 10%
of high-risk GERD patients currently undergo EGD screening
EAC has increased over 733% in the past 4 decades
less than 20%
5 year survival
Less than 10%
of EAC patients have had BE diagnosed
The Unmet Clinical Need
of EAC patients were asymptomatic prior to diagnosis
Barrett’s Esophagus screening rates are very low — even for the high-risk patients
Multiple factors contribute to the low BE screening rate, even in high-risk patients, including limited primary physician awareness of the relationship between GERD and EAC and guidelines recommending BE screening as well as reluctance to refer patients, whose symptoms may be reasonably controlled on PPIs for an “invasive” endoscopy procedure.
Since even early stage esophageal cancer carries a poor prognosis, the only opportunity to save lives is through early detection — very very early detection.
Amitabh Chak, MD, MS, FASGE
Case Western Reserve University
University Hospitals Cleveland Medical Center
Thuy-Van P. Hang, MD; Zachary Spiritos, MD, MPH; Anthony Gamboa, MD; Zhengjia Chen, PhD; Seth Force, MD; Steve Keilin, MD; Nabil Saba, MD; Bassel El-Rayes, MD; Qiang Cai, MD, PhD; Field Willingham, MD, MPH. THE EPIDEMIOLOGY OF ESOPHAGEAL ADENOCARCINOMA IN THE UNITED STATES. Program No. P0265. ACG 2018 Annual Scientific Meeting Abstracts. Philadelphia, Pennsylvania: American College of Gastroenterology.
Deloitte Analysis, on file Lucid Dx
Mikolašević, I., Bokun, T., & Filipec Kanižaj, T. (2018). Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma - where do we stand?. Croatian medical journal, 59(3), 97–99.
Gut 2015 Jan;64(1):20-5. doi: 10.1136/gutjnl-2013-305506. Epub 2014 Apr 3.